<DOC>
	<DOCNO>NCT00848302</DOCNO>
	<brief_summary>Up 30 patient low extremity disease schedule undergo diagnostic angiography undergo baseline bloodwork IVUS ( intravascular ultrasound ) , follow dose L-arginine ass change endothelial function .</brief_summary>
	<brief_title>Endothelial Function Human Arteries</brief_title>
	<detailed_description>We assess dos regional L-arginine supplementation patient undergo elective angiography lower extremity PAD . Assessment EDR EIR IVUS patent artery perform one 3 dos catheter-directed L-arginine . We obtain plasma sample peripheral artery assay amino acid level protein oxidation product use mass spectrometry . These experiment determine optimal L-arginine supplementation dose use study . We expect show L-arginine supplementation significant effect vessel less affected atherosclerosis , effect diminishes great atheroma accumulation measure IVUS virtual histology . Also , expect L-arginine supplementation effective vessel low baseline L-arginine level . Lastly , compare local arterial factor obtain via catheter-directed arterial sampling ( NOx , L-arginine , nitrotyrosine level ) traditional serum risk factor ( glucose , HbA1c , LDL , homocysteine h C-reactive protein ) .</detailed_description>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>age &gt; 18 year symptoms intermittent claudication , rest pain minor tissue loss ( Rutherford Category IV ) ABI &lt; .90 angiographic demonstration 100mm patent segment superficial femoral artery contain least one distal runoff vessel acute limb ischemia , contraindication angiography ( creatinine &gt; 2.5 ) concurrent oral anticoagulant therapy safely withhold extensive tissue loss gangrene</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>peripheral vascular disease</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>intravascular ultrasound</keyword>
	<keyword>L-Arginine</keyword>
</DOC>